Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.J&J and Legend have released new Phase III data for their drug Carvykti, showing nearly 90% of patients had no detectable cancer cells after treatment. This data could help them fend off competition from emerging CAR T therapies like Gilead and Arcellx'

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##New FDA Approval for Cancer TreatmentThe FDA has recently approved a new drug for the treatment of advanced ovarian cancer. This drug has shown promising results in clinical trials, with patients experiencing longer survival rates and fewer side effects

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Ex

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly's $3 billion investment in manufacturing capacity for tirzepatide is in the spotlight as compounding pharmacies challenge an FDA decision to end the drug shortage. Meanwhile, Amgen is making waves with a $1 billion investment, adding 370 jobs in

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Pfizer announces new vaccine distribution planPfizer has announced a new vaccine distribution plan that aims to reach more people in rural areas. The company will be partnering with local health departments and community organizations to set up vaccina

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly emerged victorious in a head-to-head weight loss battle against NovoPlus, showcasing the effectiveness of tirzepatide over semaglutide. This victory has highlighted the potential of tirzepatide in promoting weight loss, with results aligning with real

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Takeda, Roche, and Gilead have recently made significant deals in the pharmaceutical industry. Takeda's investment of up to $1.3 billion in Keros' blood cancer anemia drug is making waves, potentially challenging Bristol Myers Squibb. Roche has joined for

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis has made a deal with PTC worth up to $2.9 billion for the development of a treatment for Huntington's disease. This agreement comes shortly after PTC discontinued another asset due to disappointing phase II data. Meanwhile, companies like Merck,

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Breakthrough in Cancer Treatment ##Researchers have discovered a new combination therapy that has shown promising results in treating certain types of cancer. The therapy combines immunotherapy with targeted therapy, enhancing the body's immune respon

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.##New Drug Approval: FDA Approves First Oral Therapy for Rare Genetic DiseaseIn exciting news, the FDA has approved the first oral therapy for a rare genetic disease. This new drug is a breakthrough for patients suffering from this condition, providin